Future strategies may involve combining MTF1 inhibitors with cuproptosis and ferroptosis inducers or stratifying patients according to tumor MTF1 status, thereby overcoming drug resistance and improving therapeutic efficacy (Fig. 3). The gene discussed is MTF1; the disease is neoplasm.